Skip to Content
Merck

Skip To

M4531

Meclofenamic acid sodium salt

Synonym(s):

2-[(2,6-Dichloro-3-methylphenyl)amino]benzoic acid sodium salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice

About This Item

Linear Formula:
C14H10Cl2NO2Na
CAS Number:
Molecular Weight:
318.13
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352106
EC Number:
228-983-3
MDL number:
Assay:
≥93% (HPLC)
Form:
powder
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

synthetic (organic)

assay

≥93% (HPLC)

form

powder

solubility

water: 50 mg/mL, clear, colorless to faintly brownish-yellow, water: 50 mg/mL, clear, colorless to faintly yellow, water: 50 mg/mL, clear, colorless to very faintly brown

SMILES string

[Na].Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl

InChI

1S/C14H11Cl2NO2.Na.H/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);;

InChI key

CHGIZYUDGOIAFY-UHFFFAOYSA-N

General description

Meclofenamic acid consists of two aryl moieties that are twisted in perpendicular orientation, it includes N-2,6-dichloro-3-methylphenyl group and N-2-benzoic acid group. Because of the low aqueous solubility of the compound, it is commercially available as sodium salt.

Application

Meclofenamic acid sodium salt has been used:
  • in the inhibition of heat-induced denaturation of albumin[1]
  • as a pharmacological agent in the preparation of superfusion solution for electrophysiology studies
  • to block the gap junctions

Biochem/physiol Actions

Cyclooxygenase (IC50 = 0.6 μM) and 5-lipoxygenase (IC50 = 46.3 μM) inhibitor.
Meclofenamic acid (MFA) is a nonsteroidal anti-inflammatory, analgesic and antipyretic drug. It inhibits prostaglandin biosynthesis pathway and finds its application in the treatment of postoperative and traumatic inflammation and swelling. MFA functions in opening the potassium voltage-gated channel subfamily Q member 2/member 3 (KCNQ2/Q3).

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
D6899M127512050
form

powder

form

powder

form

powder

form

solid

assay

≥93% (HPLC)

assay

≥98% (TLC)

assay

98.0-102.0%

assay

≥95.0% (T)

solubility

water: 50 mg/mL, clear, colorless to faintly brownish-yellow, water: 50 mg/mL, clear, colorless to very faintly brown, water: 50 mg/mL, clear, colorless to faintly yellow

solubility

methanol: 50 mg/mL, clear, colorless to faint yellow or tan

solubility

water: 100 mg/mL, clear to slightly hazy, colorless to faintly yellow

solubility

H2O: soluble 1 g/10 mL, clear, colorless to faintly brownish-yellow

biological source

synthetic (organic)

biological source

synthetic

biological source

synthetic (organic)

biological source

-


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

  1. Hello, a vascular lab conducts wire myography with human (pregnant) omental resistance arteries. U46619 (cat# D8174) is used to wake up the vessels, followed by a U46619 dose-response curve to calculate an EC80. When the inhibitor meclofenamate (cat# M4531) is added, the vessels exhibit a significantly reduced constriction response to U46619, preventing the testing of a vasodilator curve (e.g. bradykinin) due to low pre-constriction.

    1 answer
    1. After adding meclofenamate, we have not specifically studied the impact on diminished U46619-induced vasoconstriction. However, based on a literature search, it is likely that meclofenamate could lead to diminished U46619-induced vasoconstriction as it is known to alter the binding of U46619 to thromboxane receptors.

      Helpful?

Reviews

No rating value

Active Filters